| | Diabetes | | | Taking Control of Glycemia in Type 2 Diabetes Patients with Cardiovascular Risk
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
Natasa Janicic-Kahric, MD, PhD
Assistant Professor of Medicine
Division of Endocrinology and Metabolism
Georgetown University Hospital
Washington, DC
| | | Mood Disorders | | | Managing Mood and Anxiety Disorders in Primary Care Practice: A Focus on Complex and Difficult-to-Treat Patients
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine Chair
Boston University School of Medicine
Chief of Family Practice
Boston Medical Center
Boston, MA
| | | Osteoarthritis | | | Optimal Use of Analgesics in the Management of Osteoarthritis Pain
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Louis C. Almekinders, MD
Professor of Orthopaedic Surgery
Duke University
Durham, North Carolina
Frank LoVecchio, DO, MPH
Professor
Arizona College of Osteopathic Medicine
Midwestern University
Glendale, Arizona
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
Lawrence D. Gelb, MD
Professor of Medicine, Department of Internal Medicine
Division of Infectious Diseases
Washington University School of Medicine
St. Louis, MO
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Gregory Brotzman, MD
Edward John Mayeaux, Jr., MD
Professor of Family Medicine, Obstetrics & Gynecology
Louisiana State University Health Sciences Center
Shreveport, LA
| | | Dyslipidemia | | | The Moving LDL Target: Getting Your Patients to Goal
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Jerome D. Cohen, MD
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
Philadelphia, PA
| | | ACS | | | Prevent The Event: Role of Oral Antiplatelet Therapy in the Management of the ACS Patient
Overview
The term acute coronary syndrome (ACS) is used to describe patients who present with either acute MI or unstable angina (UA). This program will provide an overview of ACS by discussing epidemiology, prevalance, acute and long term care treatment options as well as review current guidelines. Implementation of current treatment guidelines and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name 5 treatment recommendations for reduction of global CV risk in patients being medically managed for UA/NSTEMI
Describe 2 situations where dual antiplatelet therapy is recommended in patients with acute coronary syndrome
Faculty
Lawrence E. Mieczkowski, MD
Clinical Associate Professor of Medicine
Wright State University School of Medicine
Medical Director, Center for Cardiometabolic Treatment
Dayton, OH
| | | Osteoporosis | | | Appropriate Identification and Treatment of Non-vertebral Fractures
Overview
This program is designed to provide primary care providers with information about the state of the science and evidence-based strategies for the accurate identification and comprehensive treatment of osteoporosis.
Objectives
Identify appropriate diagnostic tools & procedures that can be employed for early diagnosis of osteoporosis
Evaluate the treatment strategies, including methods of administration and MOAs of various antiresorptive agents that are currently available to prevent fractures and treat osteoporosis
Faculty
Richard Pittsley, MD
| | | Menstrual Migraine | | | A Practical Approach to Managing Menstrual Migraine: Tailoring Treatment and Individualizing Care
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Merle L. Diamond, MD
Associate Director, Diamond Headache Clinic
Clinical Assistant Professor, Dept. of Medicine
The Chicago Medical School
Rosalind Franklin University of Medicine and Science
Chicago, IL
Lisa Mannix, MD
| | | Pain Management | | | A Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain
Overview
Four million people in the United States suffer from neuropathic pain, a condition that is often difficult to diagnose. This session, A Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain will address practical ways primary care physicians can improve recognition and treatment of neuropathic pain.
Objectives
Recognize signs and symptoms of neuropathic pain to increase identification of patients with neuropathic pain
Evaluate available treatment options for neuropathic pain and their appropriateness for your patient population to improve outcomes in these patients
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
David Bazzo, MD
| | | | | |
Overview
Objectives
Faculty
|
|
